FDA recommends sponsors plan to include race, ethnicity in clinical trial design
The US Food and Drug Administration (FDA) is recommending sponsors include a plan to increase diversity when proposing clinical trial designs for investigational products to Agency reviewers. The move is part of the Biden administration’s focus on addressing racial and ethnic disparities in health care.